Jan. 8, 2016—Sakura Finetek USA announced the acquisition of Genemed Biotechnologies’ tissue-based advanced staining business for cancer detection, diagnosis, and monitoring.
“We are pleased to add Genemed’s highly skilled and expert personnel, production facility and their extensive catalog of antibodies, probes, and detection chemistry to Sakura’s product portfolio,” Sakura CEO Takashi Tsuzuki said in a statement. “The product portfolio offered by Genemed is a perfect complement to Sakura’s hardware and software engineering competency in developing analytical instrumentation. The combination of both companies will create a powerful advanced staining solution and builds on Sakura’s commitment to develop innovative, smart automated platforms for our clinical and life science research customers.”
Genemed’s liquid-based molecular testing products were not included in the acquisition and will be spun out as an independent business. Genemed’s tissue-based advanced staining business will be integrated into Sakura Finetek with an immediate impact.
Genemed specializes in the development of antibodies, probes, detection systems, and ancillary reagents for immunohistochemistry and in-situ hybridization. In addition, Genemed offers regents for molecular testing. Its products are used for cancer testing in the clinical and life science research markets.
“Genemed and its employees are excited about the opportunity to link our highly sensitive and specific Advanced Staining products with Sakura’s highly efficient and novel fully automated advanced staining platform,” Genemed founder and CEO Dr. Dean Tsao said in a statement.